Artoss Prospective Spine Registry Outcomes

Active, not recruitingOBSERVATIONAL
Enrollment

330

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

June 30, 2025

Conditions
Spinal Fusion
Interventions
OTHER

NanoBone Bone Graft Substitute

Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.

Trial Locations (6)

20817

OrthoBethesda, Bethesda

39532

Sam Shamsnia MD Neurosurgery, Biloxi

85226

OrthoArizona, Chandler

85281

Sonoran Spine, Tempe

92108

SENTA Clinic, San Diego

06102

Hartford Health Care, Hartford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Artoss Inc.

INDUSTRY

NCT04439032 - Artoss Prospective Spine Registry Outcomes | Biotech Hunter | Biotech Hunter